• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    45 Biggest Movers From Yesterday

    12/29/21 4:06:03 AM ET
    $ADTH
    $ADTX
    $AEY
    $AGFY
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTH alert in real time by email

    Gainers

    • Insignia Systems, Inc. (NASDAQ:ISIG) shares climbed 64.8% to close at $19.02 on Tuesday as traders circulated a social media post on a potential short squeeze.
    • ShiftPixy, Inc. (NASDAQ:PIXY) surged 43.1% to settle at $1.12. ShiftPixy recently reported FY21 revenues of $23.4 million.
    • Flotek Industries, Inc. (NYSE:FTK) jumped 40.9% to settle at $0.7889 after the company announced it received an unsolicited indication of interest for a potential transaction for all or part of the company. Flotek's Board of Directors has engaged Piper Sandler & Co.
    • Pop Culture Group Co., Ltd (NASDAQ:CPOP) gained 35.9% to close at $2.31. Pop Culture Group Co., last month, said it won tender for Hanfu Cultural Festival.
    • BridgeBio Pharma, Inc. (NASDAQ:BBIO) climbed 18% to close at $13.43. HC Wainwright & Co. lowered the price target on the stock from $88 to $24, while SVB Leerink cut the price target from $66 to $24. BridgeBio Pharma shares tumbled 72% on Monday after the company's phase 3 trial to treat symptomatic transthyretin amyloid cardiomyopathy did not achieve its primary endpoint.
    • Regencell Bioscience Holdings Limited (NASDAQ:RGC) rose 16.9% to settle at $30.67. Regencell Bioscience recently appointed Dr. William Wing-Yan Lo, JP to its Board of Directors.
    • Unico American Corporation (NASDAQ:UNAM) jumped 14.8% to close at $3.3850.
    • Centogene N.V. (NASDAQ:CNTG) gained 14.4% to settle at $5.26. CENTOGENE recently said its CEO will take temporary medical leave of absence.
    • Reliance Global Group, Inc. (NASDAQ:RELI) gained 13.4% to close at $6.02. Reliance Global Group, last week, reported pricing of $20.0 million private placement with institutional investors.
    • Trean Insurance Group, Inc. (NASDAQ:TIG) jumped 12% to close at $9.16. Trean Insurance Group said its subsidiary, Benchmark Insurance Company formed a new excess and surplus lines subsidiary, Benchmark Specialty Insurance Company, an Arkansas domestic surplus lines carrier.
    • Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) gained 11.1% to close at $10.00.
    • MELI Kaszek Pioneer Corp (NASDAQ:MEKA) jumped 10.7% to settle at $12.98. MELI Kaszek Pioneer, during September, priced its initial public offering (IPO) of 25 million Class A ordinary shares at $10.00 per share.
    • Target Hospitality Corp. (NASDAQ:TH) gained 10.6% to settle at $3.5450.
    • Krispy Kreme, Inc. (NASDAQ:DNUT) jumped 10.1% to close at $17.85.
    • Krispy Kreme recently raised its FY21 outlook.
    • Gamida Cell Ltd. (NASDAQ:GMDA) climbed 9.7% to close at $2.84.
    • ADDvantage Technologies Group, Inc. (NASDAQ:AEY) rose 8.7% to close at $2.00. ADDvantage Technologies reported earnings of $0.05 per share for the fourth quarter, versus a year-ago loss of $0.09 per share.
    • BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) shares rose 6.9% to settle at $2.49. The company announced the former GSK global vaccines CFO joined the BiondVax Board of Directors.
    • Kandi Technologies Group, Inc. (NASDAQ:KNDI) gained 5.1% to settle at $3.51. Kandi Technologies Group’s wholly owned subsidiary Jiangxi Province Huiyi New Energy Co Ltd (Huiyi) has entered mass production of its lithium iron phosphate (LFP) battery IFR18650-2200mAh.
    • JinkoSolar Holding Co., Ltd. (NYSE:JKS) rose 4.6% to close at $44.10 after the company's Jinko Solar subsidiary completed IPO registration with the China Securities Regulatory Commission.


    Check out these big penny stock gainers and losers

    Losers

    • Biofrontera Inc. (NASDAQ:BFRI) shares fell 29.5% to close at $8.10.
    • Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) shares tumbled 25.5% to close at $0.6933 on Tuesday after jumping 62% on Monday.
    • Sensus Healthcare, Inc. (NASDAQ:SRTS) fell 22.7% to settle at $6.31. Sensus Healthcare recently announced the signing of an exclusive U.S. distribution agreement with Mattioli Eng. Italia for its TransDermal Infusion System non-invasive drug delivery system.
    • AdTheorent Holding Company, Inc. (NASDAQ:ADTH) tumbled 22.1% to close at $6.98.
    • Fathom Digital Manufacturing Corp. (NYSE:FATH) dipped 21.9% to close at $7.38.
    • Baudax Bio, Inc. (NASDAQ:BXRX) shares fell 21.9% to close at $0.2483 after the company announced a $4.2 million registered direct offering.
    • TOMI Environmental Solutions, Inc. (NASDAQ:TOMZ) dropped 21.8% to close at $1.72. HC Wainwright & Co. recently initiated coverage on TOMI Environmental Solns with a Buy rating and announced a price target of $3.5.
    • Aditxt, Inc. (NASDAQ:ADTX) fell 18.5% to settle at $0.5602 after the company announced a share exchange agreement to acquire AiPharma.
    • AGM Group Holdings Inc. (NASDAQ:AGMH) fell 18.4% to close at $2.97. AGM Group announced delivery of 1,335 units of crypto mining machines to Meten.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) dropped 17.5% to settle at $1.65.
    • Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) declined 16.5% to close at $10.75 after jumping over 15% on Monday.
    • Nxt-ID, Inc. (NASDAQ:NXTD) fell 15.7% to settle at $3.98 after climbing around 18% on Monday.
    • Agrify Corporation (NASDAQ:AGFY) fell 14.4% to close at $9.07.
    • Aziyo Biologics, Inc. (NASDAQ:AZYO) dropped 14% to settle at $5.47.
    • Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) dipped 13.8% to settle at $2.19.
    • Alpha Pro Tech, Ltd. (NYSE:APT) shares dropped 13.4% to close at $6.19.
    • Hyperfine, Inc. (NASDAQ:HYPR) fell 13.2% to close at $7.90.
    • Applied UV, Inc. (NASDAQ:AUVI) shares dipped 12.9% to settle at $3.58. Applied UV filed for offering of 2.4 million shares of common stock.
    • Sharecare, Inc. (NASDAQ:SHCR) fell 12.6% to close at $4.37.
    • Soluna Holdings, Inc. (NASDAQ:SLNH) fell 11.3% to close at $10.69.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) fell 10.8% to settle at $35.14.
    • Context Therapeutics Inc. (NASDAQ:CNTX) shares declined 7.4% to close at $2.90.
    • ImmunityBio, Inc. (NASDAQ:IBRX) fell 7.1% to close at $6.18. ImmunityBio was granted U.S. Patent #11,207,350 'Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer.'
    • American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) fell 7% to close at $2.39 after jumping 35% on Monday.
    • Spruce Biosciences, Inc. (NASDAQ:SPRB) fell 6.9% to close at $3.92 after jumping 13% on Monday. Oppenheimer recently initiated coverage on the stock with an Outperform rating and a $15 price target.
    • Microbot Medical Inc. (NASDAQ:MBOT) shares fell 6% to close at $8.41. Microbot Medical shares jumped 65% on Monday after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.
    Get the next $ADTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTH
    $ADTX
    $AEY
    $AGFY

    CompanyDatePrice TargetRatingAnalyst
    Flotek Industries Inc.
    $FTK
    1/29/2026$25.00Buy
    Lake Street
    BridgeBio Pharma Inc.
    $BBIO
    1/28/2026$157.00Overweight
    Barclays
    BridgeBio Pharma Inc.
    $BBIO
    1/6/2026$96.00Overweight
    Morgan Stanley
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    BridgeBio Pharma Inc.
    $BBIO
    12/11/2025$94.00Outperform
    Bernstein
    Soluna Holdings Inc.
    $SLNH
    12/11/2025$5.00Neutral → Buy
    H.C. Wainwright
    Microbot Medical Inc.
    $MBOT
    12/3/2025$5.50Buy
    Roth Capital
    Spruce Biosciences Inc.
    $SPRB
    12/3/2025$160.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $ADTH
    $ADTX
    $AEY
    $AGFY
    SEC Filings

    View All

    Spruce Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

    2/5/26 4:11:53 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    2/5/26 8:30:40 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krispy Kreme Inc. filed SEC Form 8-K: Leadership Update

    8-K - Krispy Kreme, Inc. (0001857154) (Filer)

    2/4/26 4:34:26 PM ET
    $DNUT
    Food Chains
    Consumer Staples

    $ADTH
    $ADTX
    $AEY
    $AGFY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Flotek Announces Fourth Quarter & Full Year 2025 Earnings Release and Conference Call Schedule

    HOUSTON, Feb. 6, 2026 /PRNewswire/ -- Flotek Industries, Inc. ("Flotek" or the "Company") (NYSE:FTK) today announced the Company's schedule for releasing its fourth quarter and full-year financial and operating results for the periods ended December 31, 2025. The Company plans to issue its fourth quarter and full-year 2025 financial and operating results press release after market close on Wednesday, March 11, 2026, and host its earnings conference call on Thursday, March 12, 2026, at 9:00 a.m. CT (10:00 a.m. ET).The press release will be posted on the Company's website at htt

    2/6/26 7:00:00 AM ET
    $FTK
    Major Chemicals
    Industrials

    Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

    Treatment with Weekly TA-ERT Demonstrated Rapid and Durable Normalization of Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit TA-ERT Treatment Stabilized and Preserved Cognitive and Non-Cognitive Outcomes, such as Communication and Motor Skills for Over Six-Year Period Relative to Natural History Patients Safety Profile Consistent with Intracerebroventricular Administration with ~6,000 Doses Administered Over Six-Year Period Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with signific

    2/5/26 4:05:00 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KRISPY KREME'S® New Big Game Dozen Sure to Score with Football Fans this Weekend

    Fans can also win Friday through Sunday with a $2 Original Glazed® dozen with any dozen purchase For football fans game-planning their food lineup for the weekend, Krispy Kreme's® new Big Game Dozen is a sweet play sure to win with friends and family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205847042/en/Fans can also win Friday through Sunday with a $2 Original Glazed® dozen with any dozen purchase And you don't have to wait for kickoff to score. Whether you're feeding a packed house or planning something more low-key for game day, Krispy Kreme is providing two ways for fans to be MVPs Friday through Sunday: Krisp

    2/5/26 10:04:00 AM ET
    $DNUT
    Food Chains
    Consumer Staples

    $ADTH
    $ADTX
    $AEY
    $AGFY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Khan Salman Hassan covered exercise/tax liability with 31,007 shares, decreasing direct ownership by 3% to 1,104,359 units (SEC Form 4)

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    2/6/26 9:30:00 PM ET
    $MARA
    EDP Services
    Technology

    Chief Executive Officer Thiel Frederick G covered exercise/tax liability with 67,704 shares, decreasing direct ownership by 2% to 3,409,366 units (SEC Form 4)

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    2/6/26 9:30:01 PM ET
    $MARA
    EDP Services
    Technology

    General Counsel Nowaid Zabi covered exercise/tax liability with 14,249 shares, decreasing direct ownership by 2% to 690,985 units (SEC Form 4)

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    2/6/26 9:29:58 PM ET
    $MARA
    EDP Services
    Technology

    $ADTH
    $ADTX
    $AEY
    $AGFY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Flotek Industries with a new price target

    Lake Street initiated coverage of Flotek Industries with a rating of Buy and set a new price target of $25.00

    1/29/26 8:16:37 AM ET
    $FTK
    Major Chemicals
    Industrials

    Barclays initiated coverage on BridgeBio Pharma with a new price target

    Barclays initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $157.00

    1/28/26 7:16:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on BridgeBio Pharma with a new price target

    Morgan Stanley initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $96.00

    1/6/26 8:54:42 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTH
    $ADTX
    $AEY
    $AGFY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Robertson Stephen bought $992,500 worth of shares (125,000 units at $7.94), increasing direct ownership by 39% to 445,000 units (SEC Form 4)

    4 - Target Hospitality Corp. (0001712189) (Issuer)

    12/4/25 4:47:47 PM ET
    $TH
    Hotels/Resorts
    Consumer Discretionary

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $ADTH
    $ADTX
    $AEY
    $AGFY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTH
    $ADTX
    $AEY
    $AGFY
    Leadership Updates

    Live Leadership Updates

    View All

    Soluna Appoints Michael Picchi as Chief Financial Officer

    Interim CFO David Michaels to remain on Soluna's Board following interim period Soluna Holdings, Inc. ("Soluna" or the "Company") (NASDAQ:SLNH), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, today announced it has appointed Michael Picchi as Chief Financial Officer and Treasurer, effective April 1, 2026. Picchi will lead Soluna's finance organization and support the Company's capital strategy as it scales its behind-the-meter, renewable-powered data center model and expands into Al. David Michaels, a member of Soluna's Board of Directors, has served as Interim Chief Financial Officer and Treasurer since August 2025. Michaels wil

    1/20/26 7:30:00 AM ET
    $SLNH
    EDP Services
    Technology

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Target Hospitality Announces Appointment of Chief Accounting Officer

    THE WOODLANDS, Texas, Jan. 13, 2026 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality," "Target" or the "Company") (NASDAQ:TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today announced the hiring of Cyril J. Hahamski as Chief Accounting Officer. Mr. Hahamski will oversee the Company's accounting function, including external financial reporting, internal controls, and management reporting. This appointment will further strengthen Target's internal capabilities as the Company continues to pursue a robust pipeline of growth opportunities.  Concurrent with Mr. Hahamski's appointment, Jason Vlacich w

    1/13/26 6:45:00 AM ET
    $TH
    Hotels/Resorts
    Consumer Discretionary

    $ADTH
    $ADTX
    $AEY
    $AGFY
    Financials

    Live finance-specific insights

    View All

    Flotek Announces Fourth Quarter & Full Year 2025 Earnings Release and Conference Call Schedule

    HOUSTON, Feb. 6, 2026 /PRNewswire/ -- Flotek Industries, Inc. ("Flotek" or the "Company") (NYSE:FTK) today announced the Company's schedule for releasing its fourth quarter and full-year financial and operating results for the periods ended December 31, 2025. The Company plans to issue its fourth quarter and full-year 2025 financial and operating results press release after market close on Wednesday, March 11, 2026, and host its earnings conference call on Thursday, March 12, 2026, at 9:00 a.m. CT (10:00 a.m. ET).The press release will be posted on the Company's website at htt

    2/6/26 7:00:00 AM ET
    $FTK
    Major Chemicals
    Industrials

    Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after t

    2/5/26 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

    CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].

    1/18/26 7:02:00 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTH
    $ADTX
    $AEY
    $AGFY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Agrify Corporation

    SC 13D/A - Agrify Corp (0001800637) (Subject)

    11/29/24 4:30:03 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Agrify Corporation

    SC 13D/A - Agrify Corp (0001800637) (Subject)

    11/29/24 4:30:03 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by MARA Holdings Inc.

    SC 13G/A - MARA Holdings, Inc. (0001507605) (Subject)

    11/14/24 6:13:30 PM ET
    $MARA
    EDP Services
    Technology